Changchun High-tech: Subsidiary GenSci's application for registration of 145 clinical trials has been accepted.

Changchun High-tech announced that its subsidiary, Jinsai Pharmaceutical, has received the "Acceptance Notice" issued by the National Medical Products Administration for the registration clinical trial application of GenSci145 tablets. GenSci145 tablets, as a novel selective PI3K inhibitor independently developed by Jinsai Pharmaceutical, have been shown in preclinical studies to possess strong selective inhibitory activity against various hotspot mutations in the PIK3CA helical domain and kinase domain, and demonstrate clear efficacy and good safety characteristics in animal models.